US President Donald Trump has announced deals with Eli Lilly and Novo Nordisk aimed at lowering the cost of popular weight-loss drugs, including Wegovy and Zepbound, making them more affordable for Americans.

• Consumers are expected to pay between $245 and $350 per month for these drugs, a significant reduction from over $1,000 without insurance.
• The agreements will expand Eli Lilly and Novo Nordisk's access to Medicare and Medicaid, government healthcare plans for elderly and low-income Americans.
• Approximately 10% of Medicare beneficiaries will be eligible for GLP-1 drugs at a cost of just $50, with discounted prices also available on the new direct-to-consumer TrumpRx website, launching by January.